Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

NCT05746728 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Triple-negative Breast Cancer

Interventions

DRUG: Surufatinib
DRUG: Tislelizumab

Sponsor

Huihua Xiong